Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes
Status:
Unknown status
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
Diabetic kidney disease has become the leading cause for ESRD worldwide.Albuminuria is a
major risk factor for progression of diabetic nephropathy. SGLT2 inhibitors are the first
antiglycaemic drugs with direct renoprotection, which are thought to protect the kidneys by
lowering albuminuria, stimulating urinary glucose excretion ,reducing systemic blood
pressure, while simultaneously improving multiple other risk factors in a glucose-independent
manner. However, the precise mechanisms behind the renal beneficial effect of SGLT2
inhibitors are not entirely elucidated, although ongoing outcome trials will confirm these
findings. This study is to assess the impact of three months of treatment with SGLT2
Inhibitions on different levels of albuminuria in patients with type 2 diabetes and to
evaluate the effects of SGLT2 inhibition treatment on markers for podocyte damage , renal
fibrosis, inflammation，oxidative stress and renin-angiotensin- aldosterone system.